The cells of the body are more resistant to the effects of insulin which drives the glucose into the cells and as a result increasing insulin production has the benefit of lowering blood glucose to some degree
It felt like someone finally mapped the next steps without fluff or jargon
ATTAIN-1 (NCT05869903) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes
GLP-1 agonists can cause significant gastrointestinal side effects like nausea, vomiting, and diarrhea, along with risks of pancreatitis, gallbladder issues, and gastroparesis